Dendritic cell-based tumor-specific immunotherapy against malignant brain tumor - Phase I clinical trial
Phase 1
- Conditions
- Malignant brain tumor (malignant glioma)
- Registration Number
- JPRN-UMIN000000914
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1. Within 28 days after the last treatment against cancer 2. Severe systemic infection, hematostatic dysfunction, and organ disorder 3. Steroid treatment, except used for cerebral decompression 4. Hypersensitivity to DC vaccine 5. Severe immunological disorders (autoimmune disease, immunosuppression) 6. Multiple cancers 7. Anaphylaxis to synthetic peptides
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of immunotherapy
- Secondary Outcome Measures
Name Time Method Antitumor effect, Immunological effect